Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Improved technique for measuring intense pulsed ion beams by the nuclear activation method.

The Review of scientific instruments

Blaugrund AE, Stephanakis SJ.
PMID: 18699211
Rev Sci Instrum. 1978 Jun;49(6):866. doi: 10.1063/1.1135633.

A technique capable of measuring very high ion fluences by the nuclear activation method is described. The method eliminates the adverse effects of target blowoff by placing the target in a specially designed enclosure.

Cite
Blaugrund AE, Stephanakis SJ. Improved technique for measuring intense pulsed ion beams by the nuclear activation method. Rev Sci Instrum. 1978;49(6):866doi: 10.1063/1.1135633.
Blaugrund, A. E., & Stephanakis, S. J. (1978). Improved technique for measuring intense pulsed ion beams by the nuclear activation method. The Review of scientific instruments, 49(6), 866. https://doi.org/10.1063/1.1135633
Blaugrund, A E, and Stephanakis, S J. "Improved technique for measuring intense pulsed ion beams by the nuclear activation method." The Review of scientific instruments vol. 49,6 (1978): 866. doi: https://doi.org/10.1063/1.1135633
Blaugrund AE, Stephanakis SJ. Improved technique for measuring intense pulsed ion beams by the nuclear activation method. Rev Sci Instrum. 1978 Jun;49(6):866. doi: 10.1063/1.1135633. PMID: 18699211.
Copy Download .nbib Format: NLM
RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Gueta R, Blaugrund E, Bloomenfeld A, Herbst KL.
PMID: 33867475
Dermatol Surg. 2021 Aug 01;47(8):1165-1166. doi: 10.1097/DSS.0000000000002989.

No abstract available.

Cite
Gueta R, Blaugrund E, Bloomenfeld A, et al. RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients. Dermatol Surg. 2021;47(8):1165-1166doi: 10.1097/DSS.0000000000002989.
Gueta, R., Blaugrund, E., Bloomenfeld, A., & Herbst, K. L. (2021). RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 47(8), 1165-1166. https://doi.org/10.1097/DSS.0000000000002989
Gueta, Racheli, et al. "RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients." Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] vol. 47,8 (2021): 1165-1166. doi: https://doi.org/10.1097/DSS.0000000000002989
Gueta R, Blaugrund E, Bloomenfeld A, Herbst KL. RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients. Dermatol Surg. 2021 Aug 01;47(8):1165-1166. doi: 10.1097/DSS.0000000000002989. PMID: 33867475.
Copy Download .nbib Format: NLM
Mode of Action of RZL-012, a New Fat-Reducing Molecule.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Blaugrund E, Gueta R, Zernov A, Bloomenfeld A.
PMID: 34537791
Dermatol Surg. 2021 Dec 01;47(12):1601-1605. doi: 10.1097/DSS.0000000000003245.

BACKGROUND: RZL-012 (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) is a novel investigational drug injected subcutaneously into fat tissues in patients with fat-related disorders (Dercum disease) or subjects seeking aesthetic changes.OBJECTIVE: Preclinical studies were undertaken to understand RZL-012's mechanism of action.MATERIALS AND METHODS: The...

Cite
Blaugrund E, Gueta R, Zernov A, et al. Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatol Surg. 2021;47(12):1601-1605doi: 10.1097/DSS.0000000000003245.
Blaugrund, E., Gueta, R., Zernov, A., & Bloomenfeld, A. (2021). Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 47(12), 1601-1605. https://doi.org/10.1097/DSS.0000000000003245
Blaugrund, Eran, et al. "Mode of Action of RZL-012, a New Fat-Reducing Molecule." Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] vol. 47,12 (2021): 1601-1605. doi: https://doi.org/10.1097/DSS.0000000000003245
Blaugrund E, Gueta R, Zernov A, Bloomenfeld A. Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatol Surg. 2021 Dec 01;47(12):1601-1605. doi: 10.1097/DSS.0000000000003245. PMID: 34537791; PMCID: PMC8612913.
Copy Download .nbib Format: NLM
Mode of Action of RZL-012, a New Fat-Reducing Molecule.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Blaugrund E, Gueta R, Zernov A, Bloomenfeld A.
PMID: 34537791
Dermatol Surg. 2021 Dec 01;47(12):1601-1605. doi: 10.1097/DSS.0000000000003245.

BACKGROUND: RZL-012 (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) is a novel investigational drug injected subcutaneously into fat tissues in patients with fat-related disorders (Dercum disease) or subjects seeking aesthetic changes.OBJECTIVE: Preclinical studies were undertaken to understand RZL-012's mechanism of action.MATERIALS AND METHODS: The...

Cite
Blaugrund E, Gueta R, Zernov A, et al. Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatol Surg. 2021;47(12):1601-1605doi: 10.1097/DSS.0000000000003245.
Blaugrund, E., Gueta, R., Zernov, A., & Bloomenfeld, A. (2021). Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 47(12), 1601-1605. https://doi.org/10.1097/DSS.0000000000003245
Blaugrund, Eran, et al. "Mode of Action of RZL-012, a New Fat-Reducing Molecule." Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] vol. 47,12 (2021): 1601-1605. doi: https://doi.org/10.1097/DSS.0000000000003245
Blaugrund E, Gueta R, Zernov A, Bloomenfeld A. Mode of Action of RZL-012, a New Fat-Reducing Molecule. Dermatol Surg. 2021 Dec 01;47(12):1601-1605. doi: 10.1097/DSS.0000000000003245. PMID: 34537791; PMCID: PMC8612913.
Copy Download .nbib Format: NLM
Panel discussion.

Bulletin of the New York Academy of Medicine

Petti G, Biller HS, Blaugrund S.
PMID: 19312902
Bull N Y Acad Med. 1973 Oct;49(10):920-1.

No abstract available.

Cite
Petti G, Biller HS, Blaugrund S. Panel discussion. Bull N Y Acad Med. 1973;49(10):920-1
Petti, G., Biller, H. S., & Blaugrund, S. (1973). Panel discussion. Bulletin of the New York Academy of Medicine, 49(10), 920-1.
Petti, G, et al. "Panel discussion." Bulletin of the New York Academy of Medicine vol. 49,10 (1973): 920-1.
Petti G, Biller HS, Blaugrund S. Panel discussion. Bull N Y Acad Med. 1973 Oct;49(10):920-1. PMID: 19312902; PMCID: PMC1807105.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries